Interestingly, lenvatinib, but not sorafenib, decreases the CD133+/CD44+ CSC population in HCC preclinical models by blocking FGFR1-3 signaling, which is indeed one of the main differences between these two drugs. Here, CD44 is linked to hepatocellular carcinoma.